Abbvie’s RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis May 4, 2022 | BioForward Member News Read the full Abbvie press release here
Aug 17 2022 BioForward & Fisher Scientific Customer Appreciation Luncheon BioForward's New Office at URP